Halozyme Therapeutics Investor Presentation — November 2022

Document content

Halozyme Confidential and ProprietaryThird Quarter2022

Financialand Operating Results

November 8, 2022Halozyme Confidential and Proprietary 2

Inaddition tohistorical information, thestatements setforth inthispresentation include forward -looking statements including, without limitation, statements concerning the

Company’s expected future financial performance (including the Company's financial outlook for2022 )and expectations forprofitability, revenue (including

expectations forfuture milestones and royalties), operating income, and earnings -per-share, and theCompany’s plans torepurchase shares under itsshare repurchase

program and topotentially expand the Company's platform through acquisitions .Forward -looking statements regarding the Company’s ENHANZE®drug delivery

technology may include thepossible benefits and attributes ofENHANZE®including itspotential application toaidinthedispersion and absorption ofother injected

therapeutic drugs and facilitating more rapid delivery and administration oflarger volumes ofinjectable medications through subcutaneous delivery .Forward -looking

statements may also include potential growth driven byourand ourpartners' development and commercialization efforts (including anticipated new clinical trialstarts ,

pipeline advancements, product approvals and commercial launches ),projections forfuture sales revenue ofourpartners ’products, potential new ENHANZE®and other

collaborations ,collaborative targets and indications forENHANZE®products, co-formulation intellectual property and theCompany’s plans todevelop alarge volume

autoinjector and new formulations ofitsAPIforlonger intellectual property protection .These forward -looking statements aretypically, butnotalways, identified through

useofthewords "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other

words ofsimilar meaning and involve riskand uncertainties that could cause actual results todiffer materially from those intheforward -looking statements .Actual results

could differ materially from theexpectations contained inthese forward -looking statements asaresult ofseveral factors, including unexpected levels ofrevenues

(including royalty and milestone revenue received from ourcollaboration partners), expenditures and costs, unexpected delays intheexecution oftheCompany’s share

repurchase program ,unexpected results ordelays inthegrowth oftheCompany’s ENHANZE® business, obtaining new co-formulation intellectual property, orinthe

development, regulatory review orcommercialization ofnew formulations oftheCompany’s APIoritsproprietary orpartnered products, including any potential delays